Heart protection study was multicentric, randomised, placebo controlled study in which was involved 20 536 patients (5 963 diabetics) with risk factors for the CAD. Primary endpoit was mortality and mortality due to cardiovascular diseases.
Treatment with 40 mg simvastatin (ZOCOR(R)) reduced risk of total mortality (12 %), cardiovascular mortality (18 %), incidence of the major cariovascular events (27 %). The same effect was shown in diabetic subpopulation (24 % reduction of cardiovascular events).
It must be discussion about a new criterion for the intervention in high cardiovascular risk pupulation. Treatments target in diabetic populations is a normoglycaemia, normotension and statins now.